Agios Pharmaceuticals Inc (STU:8AP)
€ 56 0 (0%) Market Cap: 3.20 Bil Enterprise Value: 2.30 Bil PE Ratio: 5.18 PB Ratio: 2.06 GF Score: 28/100

Q4 2023 Agios Pharmaceuticals Inc Earnings Call Transcript

Feb 15, 2024 / 01:00PM GMT
Release Date Price: €24 (+3.45%)
Operator

Good morning and welcome to Agios' Fourth Quarter 2023 conference call. At this time, all participants are in a listen only mode. There'll be a question and answer session at the end. Please be advised that this call is being recorded our deals request.

I would now like to turn the call over to Chris Taylor, Vice President, Investor Relations and Corporate Communications for Agios. Please go ahead.

Christopher Taylor
Agios Pharmaceuticals Inc - Vice President, Investor Relations and Corporate Communications

Thank you, operator. Good morning, everyone, and welcome to Agios' conference call and webcast to discuss fourth quarter and full year 2023 financial results. And recent business highlights. You can access slides for today's call by going to the Investors section of our website at Agios.com. On today's call, I'm joined by our Chief Executive Officer, Brian Goff, Dr. Sarah Hewitt's, Chief Medical Officer and Head of Research and Development Center melanoma, our Chief Commercial Officer, and Cecilia Jones, Chief Financial Officer.

Before we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot